Business Context and Reporting Period
Coherus BioSciences, Inc. (CHRS) filed a Form 8-K on December 2, 2024, reporting the entry into a Material Definitive Agreement. On this date, the Company entered into an Asset Purchase Agreement with Intas Pharmaceuticals Ltd. to divest its UDENYCA (pegfilgrastim-cbqv) franchise, including the UDENYCA ONBODY injector presentation.
Key Financial Metrics and Transaction Terms
The filing details a strategic divestiture rather than standard periodic financial results. Key financial terms of the transaction include:
- Base Consideration: $483.4 million in cash.
- Inventory Component: The base consideration includes $118.4 million attributed to UDENYCA product inventory, subject to downward adjustment based on actual inventory delivered at closing.
- Contingent Consideration (Earn-outs): The Company is eligible for two additional payments of $37.5 million each (totaling $75 million), contingent on Net Sales milestones:
- First payment: Net Sales of $300 million for four consecutive fiscal quarters within the first five full fiscal quarters post-closing.
- Second payment: Net Sales of $350 million for four consecutive fiscal quarters within the first seven full fiscal quarters post-closing.
- Termination Fees:
- $16.8 million payable by Coherus to Intas if the agreement is terminated by Coherus to pursue a superior proposal or if the Board withdraws its recommendation.
- $1.0 million payable by Coherus to Intas upon termination by Coherus in certain other specified circumstances.
The filing does not provide current revenue, profit, cash flow, or debt metrics for the Company as a whole, as this is a current report regarding a specific transaction.
Material Changes and Transaction Status
The primary material change is the agreement to sell the UDENYCA business, which represents a significant shift in the Company's asset base. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.
Key conditions precedent include:
- Approval by Coherus stockholders at a special meeting.
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).
- Clearance from the Committee on Foreign Investment in the United States (CFIUS).
- Absence of any order or injunction prohibiting the transaction.
- Accuracy of representations and warranties and compliance with covenants.
- No Material Adverse Effect occurring since the agreement date.
- Specific packaging and labeling conditions related to Contract Manufacturing Organizations (CMOs) and FDA authorization.
Guidance, Outlook, and Risks
Management Commentary: The Board of Directors has unanimously approved the agreement and declared it in the best interest of the Company and its stockholders, recommending adoption by stockholders. The Company anticipates closing in Q1 2025.
Risks and Contingencies:
- Transaction Failure: The deal may not close due to regulatory delays, failure to obtain stockholder approval, or the occurrence of a Material Adverse Effect.
- Termination Fees: The Company faces potential cash outflows of up to $16.8 million if it terminates the agreement to pursue a superior proposal.
- Earn-out Uncertainty: The additional $75 million in consideration is not guaranteed and depends on future sales performance by Intas.
- Operational Disruption: The transaction may disrupt current plans, divert management attention, or impact relationships with employees and partners.
Forward-Looking Statements: The filing contains numerous forward-looking statements regarding the timing of closing, regulatory approvals, and future financial performance, which are subject to inherent risks and uncertainties.
Investor Verification Checklist
- Verify the outcome of the special stockholder meeting regarding the approval of the Asset Purchase Agreement.
- Monitor regulatory filings for the status of HSR Act waiting periods and CFIUS clearance.
- Review the upcoming proxy statement (Schedule 14A) for detailed risk factors and the definitive terms of the transaction.
- Assess the Company's remaining business portfolio and liquidity position post-divestiture, as the UDENYCA franchise is a major asset.
- Track the actual inventory levels at closing to determine if the $118.4 million inventory target will be met or adjusted downward.